Posted by Michael Wonder on 08 Feb 2017
FDA approves Amgen's Parsabiv (etelcalcetide), first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis
7 February 2017 - Intravenous administration puts delivery in hands of health care provider.
Amgen today announced that the U.S. FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis.
Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the haemodialysis session.
